A Study of Endobiliary Radiofrequency Ablation in Malignant Biliary Obstructions
- Conditions
- Biliary Stricture
- Interventions
- Procedure: Temperature-sensitive radiofrequency ablationOther: No intervention
- Registration Number
- NCT05826639
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The purpose of this study is to assess the impact of temperature-sensitive radiofrequency ablation (RFA) immediately before biliary stent placement on duration of biliary stent patency and re-intervention free survival. This is a research study meant to collect information to help other patients with malignant biliary strictures in the future.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 500
- Malignant biliary stricture
- Biopsy-confirmed pancreaticobiliary or ampullary malignancy that have agreed to undergo radiofrequency ablation with placement of biliary stents
- Patients with life expectancy greater than 3 months
- Patients who are pregnant, have cirrhosis, or significant liver metastasis >30% on radiologic imaging suggestive of poor liver function that will not improve despite endoscopic drainage.
- Patients who have undergone prior biliary decompression stents or percutaneous drainage that cannot be removed at time of ERCP and thus preclude effective radiofrequency ablation
- Patients with altered anatomy unable to undergo conventional ERCP
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Temperature-sensitive RFA prior to biliary stenting Temperature-sensitive radiofrequency ablation Data will be collected on subjects undergoing endoscopic retrograde cholangiopancreatography (ERCP) with temperature-sensitive RFA prior to biliary stenting for treatment of malignant biliary strictures as part of clinical care. Non-RFA biliary stenting for malignant biliary obstruction No intervention Retrospective participants that have undergone non-RFA biliary stenting for malignant biliary obstruction from a historical cohort will serve as controls.
- Primary Outcome Measures
Name Time Method Stent patency 6 months Duration of stent patency over the 6 month follow-up period
Re-intervention free survival 6 months Duration of re-intervention free survival over the 6 month follow-up period
Mortality 6 months Number of subject deaths following ERCP, over the 6-month follow-up period
- Secondary Outcome Measures
Name Time Method Adverse Events 6 months Number of participants with treatment-related adverse events over the 6-month follow-up period
Time until first adverse event 6 months Time (in days) from ERCP until first treatment-related adverse event, over the 6-month follow-up period
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States